Want to join the conversation?
Global pharmaceutical giant $ABBV announced that its product candidate for treatment of rheumatoid arthritis, selective JAK1 inhibitor ABT-494, has successfully achieved its primary endpoint in two Phase 2 studies."We are encouraged by Phase 2 results & we'll advance ABT-494 to Phase 3 studies with once-daily formulation," said Mike, EVP R&D & CSO.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?